Lewy bodies are intracellular fibrillar inclusions comprised of α-synuclein. They constitute the pathological hallmark of Parkinson's disease, Dementia with Lewy bodies and other neurodegenerative diseases. Although the majority of Lewy bodies are stained for ubiquitin by immunohistochemistry, the substrate for this modification is poorly understood. Insoluble, urea-soluble α-synuclein was separated from soluble fractions and subjected to 2-dimensional gel electrophoresis, to further characterize pathogenic α-synuclein species from disease brains. Using this approach we found that in sporadic Lewy body diseases a highly modified, disease-associated 22-24kDa α-synuclein species is ubiquitinated. Conjugation of one, two and to a lesser extent three ubiquitins was detected. This 22-24kDa α-synuclein species represents partly phosphorylated protein.
Ubiquitination of modified α-synuclein in Lewy bodies centrifuged at 15 000 rpm for 5 min at 4 o C. Fifty µg of each sample was assayed for the chymotrypsin-like activity of the proteasome as previously described (8) 
Results:
Immunohistochemistry:
PD and DLB cases with mild to moderate cell loss were selected to avoid artefacts related to extensive cell death. Immunohistochemistry with anti-α-synuclein antibodies showed several LB, pale bodies and Lewy neurites in both DLB and PD ( Fig. 1A and B).
In serial sections anti-ubiquitin antibodies stained only some of the α-synuclein positive inclusions (Fig. 1C) .
Fractionation of α-synuclein from human brain:
To investigate the extent to which LB-associated α-synuclein is posttranslationally modified, we used a method that is a modification of a previously reported protocol (6, 7) and allows the separation of all forms of aggregated α-synuclein from soluble fractions. This is based on differential fractionation under conditions which do not solubilize the aggregates but simply separate them from the bulk of cytoplasmic and membrane proteins. The main purpose of this approach was to identify conditions, which maximise the recovery of all LB-associated forms α-synuclein (both filamentous and non-filamentous). The different fractions were analysed by conventional immunoblotting.
Similar α-synuclein reactivity was detected in cytoplasmic and membrane fractions from SN, frontal and cingulate cortex of extracts from PD, DLB and control brains as shown in Fig. 2A . In these fractions, α-synuclein was detected using Syn-1 antibody as a single band of 19kDa in accordance with the apparent molecular weight of full-length protein in both disease cases and controls (5, 9) . No higher molecular weight α-synuclein bands were detected.
Ubiquitination of modified α-synuclein in Lewy bodies
In contrast to control brains, in which urea-soluble extracts were virtually devoid of α-synuclein, strong immunoreactivity was found in urea-soluble extracts from PD and DLB (Fig. 2B ). Oligomeric and higher molecular weight aggregates were the predominant species in this fraction. At lower molecular weight, when compared to recombinant protein, three distinct bands were detected with Syn-1 antibody, which recognizes the first 120 residues of the protein: One corresponding to monomeric α-synuclein (19kDa), a novel 22-24kDa band as well as truncated α-synuclein (15kDa).
These bands were examined using a panel of antibodies raised against distinct epitopes ( Fig. 2C and D) . The 19kDa and 22-24kDa bands but not the 15kDa truncated protein were detected with LB509 antibody and PER4 antiserum, both directed against the carboxy-terminus of the protein (10). These results indicated that the 15kDa band is a carboxy-terminal truncated protein whilst the 19kDa and 22-24kDa are comprised of fulllength protein.
Since, a glycosylated form of α-synuclein with a molecular weight of 22-24kDa
was identified in cases of juvenile onset parkinsonism with mutations in the parkin gene (11), we investigated whether the 22-24kDa α-synuclein is glycosylated by treating our extracts from sporadic LB disease with the same deglycosylating enzymes as those used by Shimura et al. (11). We found that these enzymes, at the conditions used by Shimura et al., did not alter the electrophoretic mobility of the 22-24kDa α-synuclein band to the 19kDa position as detected with LB509 (Fig. 3A) . In parallel control experiments, a significant reduction of glycosylated proteins was detected with concanavalin A (Fig.   3B ). Deglycosylation of bovine fetuin used as positive control was detected by
Coomassie stain as a shift in the electrophoretic mobility of the protein from 75kDa to 50kDa (data not shown).
Lewy body-associated α-synuclein immunoreactivity using 2-DE:
In an attempt to investigate further the characteristics of disease-associated α-synuclein, urea-soluble fractions from disease cases and controls were subjected to further separation across a pH gradient of 3 to 10, before proteins were separated according to their molecular weight, i.e. 2-DE. To determine the electrophoretic mobility Ubiquitination of modified α-synuclein in Lewy bodies of monomeric full-length α-synuclein in 2-DE we loaded recombinant protein, which was found to run at the expected apparent molecular weight of 19kDa as in onedimentional electrophoresis and pI of 4.4 (Fig. 4B) . In brain regions with LB, α-synuclein immunoreactivity gave a characteristic pattern on 2-DE analysis which consisted of serial spots of similar molecular weight but different charge, as well as high molecular weight smears (Fig. 4A ). This pattern was never detected in control cases.
When extracted α-synuclein was compared to the recombinant protein, we detected the full-length protein at 19kDa, a truncated form at a lower molecular weight around 15 kDa 
Modified 22-24kDa α-synuclein is ubiquitinated:
Although, the majority of LB are stained with antibodies to ubiquitin, the nature of the ubiquitinated protein(s) in these inclusions is uncertain. Ligation of each molecule of ubiquitin increases the apparent molecular mass of a protein on SDS-PAGE by 6-8 kDa and shifts its pI toward that of ubiquitin (pI 6.8). Urea-soluble extracts from PD and DLB were therefore subjected to 2-D SDS-PAGE followed by immunoblotting with either ubiquitin antiserum or anti-α-synuclein antibodies. This showed that some of the α-synuclein-positive pH separated spots represent an ubiquitinated form of the protein ( Ubiquitination of modified α-synuclein in Lewy bodies involvement. We found that although there was a reduction in proteasome activity in brain regions with AD pathology, no significant decline was detected in DLB ( Fig. 7E and F).
Discussion:
In this study we have shown the first analysis of LB-associated α-synuclein based on solubility, charge and molecular weight. Using this approach it is shown that in diseased tissue, a modified 22-24kDa α-synuclein is a substrate for oligo-ubiquitination.
Furthermore, the proteolytic activity of the proteasome in areas with LB-associated 22-24kDa α-synuclein was not invariably impaired.
A number of studies have shown that ubiquitin and enzymes of the ubiquitin system are found in LB, but the nature of the substrate for ubiquitination remains unclear.
Although we could detect poly-ubiquitinated proteins in all sub-cellular fractions examined, ubiquitinated α-synuclein was extracted biochemically only with diseaseassociated insoluble aggregates and not in soluble fractions. In 2-DE analysis, ubiquitinated α-synuclein gave a characteristic pattern of serial spots ranging from about 29 kDa to 43 kDa, separated by about 7 kDa and shifted towards a pI of 6.8 as expected
by the addition of a free ubiquitin molecule. Our data clearly show that mainly one or two and to a lesser extent three ubiquitin moieties are conjugated on LB-associated α-synuclein. This pattern is remarkably similar to that of tau in paired helical filaments of neurofibrillary tangles, which is mainly mono-ubiquitinated (13) . It is well established that for ubiquitin-dependent degradation to occur conjugation of at least 4 ubiquitins on a protein is necessary (14) . We and others have previously shown that ubiquitination of unmodified α-synuclein does not occur following inhibition of the proteasome in transfected cells (8, (15) (16) (17) (18) . This is in agreement with the present data, which show that the 19kDa monomeric α-synuclein is not ubiquitinated. Taken together, these data support the notion that, ubiquitin-dependent degradation is unlikely to be a major physiological mechanism for α-synuclein degradation. Rather, ubiquitination of LB-Ubiquitination of modified α-synuclein in Lewy bodies associated α-synuclein most likely represents a disease-specific pathway. In this respect, there are two obvious possibilities: ubiquitination could represent an unsuccessful "lastditch stand" of cells in their attempt to unfold and/or degrade misfolded proteins either through the proteasome, which requires poly-ubiquitination or the lysosome which requires mono-ubiquitination (19) . Alternatively it could represent a cytoprotective response to preclude interactions of inappropriately exposed domains (20) . Which one of these possibilities is more likely remains to be seen.
In keeping with ubiquitination being a disease-specific pathway is the finding that it is almost invariably associated with further post-translational modifications. Since ligation of each molecule of ubiquitin increases the apparent molecular mass of a protein by 6-8 kDa and shifts its pI towards that of ubiquitin (pI 6.8), electrophoretic resolution of ubiquitin-protein conjugates by both charge and mass can provide insight into the identity of ubiquitinated substrates. Using 2-DE, we show here for the first time that in sporadic LB diseases, a 22-24kDa α-synuclein species and not monomeric protein is the substrate for oligo-ubiquitination. This is in contrast to a recent study, which reported that monomeric α-synuclein is oligo-ubiquitinated (21). This difference could be explained by the fact that Hasewaga et al. analysed samples, which were prepared using a sarkosylbased method and therefore are enriched mainly in filamentous α-synuclein. In contrast, our samples contained both filamentous and non-filamentous α-synuclein from early stages. Furthermore, we and others (22-24) find that monomeric full-length α-synuclein runs with an apparent molecular weight of 19kDa whereas in Hasewaga et al., this is shown at 15 kDa. This discrepancy makes it difficult to predict whether our 22-24kDa non-ubiquitinated α-synuclein band is the same as what they describe as monomeric ubiquitinated α-synuclein. However, it is possible that momoneric α-synuclein becomes ubiquitinated at later stages of disease and is detected in filament preparations. We found that some of the 22-24kDa α-synuclein is phosphorylated on serine residues whilst only a few higher molecular weight forms were positive with anti-phosphotyrosine antibodies shown to be a substrate for ubiquitination by UCH-L1, which contrary to the conventional understanding of the ubiquitin system acts in an ATP-independent manner (25) .
Whether α-synuclein is a substrate for the proteasome has been a subject of debate (15, 16) . We subsequently showed that unmodified full-length α-synuclein is degraded directly by the 20S proteasome in an ubiquitin-independent manner (8). Since α-synuclein is a natively unfolded protein, it is feasible that in vivo, unfolded α-synuclein could bypass the need for ubiquitination and unfolding and enter the 20S proteasome directly. The above is in accordance with the finding that other small relatively unfolded proteins can be degraded by the proteasome in an ubiquitin-independent manner (26, 27 ).
An earlier report has shown that proteasome activity is reduced in the SN of PD patients (28) . It is therefore feasible that accumulation of α-synuclein is associated with proteasome dysfunction. However, LB-associated α-synuclein is also found outside the SN and therefore all regions should be investigated. We found significant reduction in the proteolytic activity of the proteasome in the SN from PD and DLB cases but not in other If the proteolytic system is overwhelmed by modified α-synuclein species, then α-synuclein fragments, generated as a result of aberrant proteolysis could be found specifically in association with LB. Accordingly, we found that truncated α-synuclein is selectively recovered from fractions containing aggregated α-synuclein but not in controls. Characterization of these fragments shows that they represent carboxy-terminal truncated protein. Since in fibrils both the amino-and carboxyl-terminal portions of α-synuclein extend out in the periphery (30) , the detection of only carboxy-terminal truncated protein is unlikely to be an artefact of extraction. Previous studies have reported the existence of truncated α-synuclein (6, 7, 31) . In contrast to data presented here, truncated α-synuclein protein was found in both soluble and insoluble fractions and was equally present in soluble fractions from disease and control cases (6, 7) . α-Synuclein is susceptible to nonenzymatic hydrolysis (32) and a number of proteolytic digestion fragments are readily generated during purification procedures that involve formic acid Ubiquitination of modified α-synuclein in Lewy bodies extraction (31) and sonication (6, 7) . Therefore, the extraction method might confound previous suggestions that truncated α-synuclein is a normal soluble breakdown product.
With our extraction procedure degradation products are unlikely to form, suggesting that aberrant proteolysis, either by the proteasome or other proteases could be a feature of neurodegeneration associated with LB formation. The finding that α-synuclein is degraded by the proteasome at internal peptide bonds without ubiquitination (33) suggests that the 20S proteasome could contribute to the formation of these fragments.
In summary, we have shown that in PD and DLB, a modified 22-24kDa α-synuclein is a substrate for oligo-ubiquitination, which occurs in the absence of a generalized significant impairment of the proteolytic activity of the proteasome. Since unmodified α-synuclein is degraded by the proteasome in an ubiquitin-independent manner (8) our data suggest that accumulation of modified 22-24kDa α-synuclein is a disease-specific event that may overwhelm the proteolytic system, presumably due to Note the characteristic pattern of spots (asterisks) immunoreactive for both α-synuclein and ubiquitin at about 29, 36 and to a lesser extent 43kDa separated by a charge shift and a size shift corresponding to the addition of a single ubiquitin. The modified 22-24kDa α-synuclein spots (arrow) is not positive for ubiquitin but when compared to monoubiquitinated α-synuclein show the appropriate decrease in size and charge shift that corresponds to the putative substrate for ubiquitination. Full-length α-synuclein has an apparent molecular weight of 19kDa (arrowhead).
